The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...

Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...

More than 60 years of work by local artist Dave Nixon is exhibited in the Mari Sandoz High Plains Heritage Center.

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...

Sandoz (SDZNY) announced the launch of Pyzchiva in the U.S. The medicine is now commercially available to patients across the U.S. Discover ...

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...